Hansoh Pharmaceutical Group Company Limited
3692
Classement en actions
#904
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Prix de l'action
$4.40
Capitalisation boursière
$26.66B
Changement (1 jour)
0.00%
Changement (1 an)
-4.79%
Pays
CN
Échange Hansoh Pharmaceutical Group Company Limited (3692)
Catégorie
Healthcare
Bénéfices pour Hansoh Pharmaceutical Group Company Limited (3692)
Bénéfices en Jun 2026 TTM : $1.14B
Selon les derniers rapports financiers de Hansoh Pharmaceutical Group Company Limited, les bénéfices actuels de l'entreprise sont de $1.14B. En 2023, l'entreprise a réalisé un bénéfice de $532.05M, une augmentation par rapport à celui de 2022 qui était de $427.44M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Hansoh Pharmaceutical Group Company Limited de 2016 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $1.14B | 63.74% |
| 2024 | $696.69M | 30.94% |
| 2023 | $532.05M | 24.47% |
| 2022 | $427.44M | -17.68% |
| 2021 | $519.22M | 9.48% |
| 2020 | $474.28M | 10.05% |
| 2019 | $430.96M | 28.37% |
| 2018 | $335.73M | 13.01% |
| 2017 | $297.07M | 14.31% |
| 2016 | $259.87M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 54.69% |
IN
|
